Equities Analysts Offer Predictions for ARCT Q3 Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Investment analysts at William Blair boosted their Q3 2025 earnings per share estimates for Arcturus Therapeutics in a research note issued on Tuesday, August 12th. William Blair analyst M. Minter now anticipates that the biotechnology company will earn ($0.58) per share for the quarter, up from their previous estimate of ($0.81). The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.22) per share. William Blair also issued estimates for Arcturus Therapeutics’ Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($2.15) EPS, Q1 2026 earnings at ($0.45) EPS, Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.68) EPS and FY2027 earnings at $1.83 EPS.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($1.11) by $0.77. The company had revenue of $28.30 million during the quarter, compared to analyst estimates of $17.64 million. Arcturus Therapeutics had a negative return on equity of 24.87% and a negative net margin of 49.26%.

Other equities research analysts have also issued reports about the company. Wall Street Zen upgraded Arcturus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Wells Fargo & Company dropped their price target on Arcturus Therapeutics from $45.00 to $42.00 and set an “overweight” rating for the company in a research note on Tuesday. Canaccord Genuity Group dropped their price target on Arcturus Therapeutics from $68.00 to $66.00 and set a “buy” rating for the company in a research note on Tuesday, May 13th. Citigroup restated a “buy” rating and set a $49.00 price target (up from $47.00) on shares of Arcturus Therapeutics in a research note on Tuesday. Finally, Scotiabank restated an “outperform” rating on shares of Arcturus Therapeutics in a research note on Wednesday, July 2nd. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $50.00.

Arcturus Therapeutics Price Performance

Shares of NASDAQ:ARCT opened at $19.23 on Thursday. The firm has a market capitalization of $522.29 million, a PE ratio of -8.62 and a beta of 2.26. The business has a 50-day moving average of $13.44 and a two-hundred day moving average of $13.31. Arcturus Therapeutics has a 12 month low of $8.04 and a 12 month high of $25.88.

Institutional Investors Weigh In On Arcturus Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. ARK Investment Management LLC boosted its position in shares of Arcturus Therapeutics by 3.9% in the first quarter. ARK Investment Management LLC now owns 2,008,480 shares of the biotechnology company’s stock worth $21,270,000 after buying an additional 74,629 shares during the period. Vanguard Group Inc. boosted its position in shares of Arcturus Therapeutics by 3.8% in the first quarter. Vanguard Group Inc. now owns 1,748,928 shares of the biotechnology company’s stock worth $18,521,000 after buying an additional 64,367 shares during the period. Schonfeld Strategic Advisors LLC boosted its holdings in Arcturus Therapeutics by 129.7% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 849,081 shares of the biotechnology company’s stock valued at $14,409,000 after purchasing an additional 479,482 shares during the last quarter. Woodline Partners LP boosted its holdings in Arcturus Therapeutics by 3.5% in the fourth quarter. Woodline Partners LP now owns 806,912 shares of the biotechnology company’s stock valued at $13,693,000 after purchasing an additional 26,956 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Arcturus Therapeutics by 6.4% in the second quarter. Geode Capital Management LLC now owns 606,291 shares of the biotechnology company’s stock valued at $7,889,000 after purchasing an additional 36,671 shares during the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.